Your browser doesn't support javascript.
loading
Gliomatosis cerebri (GC) growth pattern: A single-center analysis of clinical, histological, and molecular characteristics of GC and non-GC glioblastoma.
Divé, Iris; Weber, Katharina J; Hartung, Tabea I; Steidl, Eike; Wagner, Marlies; Hattingen, Elke; Franz, Kea; Fokas, Emmanouil; Ronellenfitsch, Michael W; Herrlinger, Ulrich; Harter, Patrick N; Steinbach, Joachim P.
Affiliation
  • Divé I; Dr. Senckenberg Institute of Neurooncology, Goethe University, Frankfurt am Main, Germany.
  • Weber KJ; University Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
  • Hartung TI; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.
  • Steidl E; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.
  • Wagner M; University Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
  • Hattingen E; Frankfurt Cancer Institute (FCI), Goethe University, Frankfurt am Main, Germany.
  • Franz K; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.
  • Fokas E; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt am Main, Germany.
  • Ronellenfitsch MW; Institute of Neurology (Edinger-Institute), Goethe University, Frankfurt am Main, Germany.
  • Herrlinger U; University Cancer Center Frankfurt (UCT), Goethe University, Frankfurt am Main, Germany.
  • Harter PN; German Cancer Consortium (DKTK), Partner Site Frankfurt/Mainz, Frankfurt am Main, Germany.
  • Steinbach JP; Institute of Neuroradiology, Goethe University, Frankfurt am Main, Germany.
Neurooncol Adv ; 5(1): vdad131, 2023.
Article in En | MEDLINE | ID: mdl-38024242
ABSTRACT

Background:

The biological understanding of glioblastoma (GB) with gliomatosis cerebri (GC) pattern is poor due to the absence of GC-specific studies. Here, we aimed to identify molecular or clinical parameters that drive GC growth.

Methods:

From our methylome database of IDH (isocitrate dehydrogenase)-wildtype GB, we identified 158 non-GC and 65 GC cases. GC cases were subdivided into diffuse-infiltrative (subtype 1), multifocal (subtype 2), or tumors with 1 solid mass (subtype 3). We compared clinical, histological, and molecular parameters and conducted a reference-free tumor deconvolution of DNA methylation data based on latent methylation components (LMC).

Results:

GC subtype 1 less frequently showed contrast-enhancing tumors, and more frequently lacked morphological GB criteria despite displaying GB DNA methylation profile. However, the tumor deconvolution did not deliver a specific LMC cluster for either of the GC subtypes. Employing the reference-based analysis MethylCIBERSORT, we did not identify significant differences in tumor cell composition. The majority of both GC and non-GC patients received radiochemotherapy as first-line treatment, but there was a major imbalance for resection. The entire GC cohort had significantly shorter overall survival (OS) and time to treatment failure (TTF) than the non-GC cohort. However, when filtering for cases in which only stereotactic biopsy was performed, the comparison of OS and TTF lost statistical significance.

Conclusions:

Our study offers clinically relevant information by demonstrating a similar outcome for GB with GC growth pattern in the surgically matched analysis. The limited number of cases in the GC subgroups encourages the validation of our DNA methylation analysis in larger cohorts.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2023 Document type: Article Affiliation country: Germany

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Neurooncol Adv Year: 2023 Document type: Article Affiliation country: Germany
...